Q2
AHCO — Q2 2026 Financial Report Analysis
AdaptHealth grew Q2 2026 revenue 12.7% to $740.3M on new capitated contracts, but adjusted EBITDA margin fell to 17.8%, a $144.2M goodwill charge drove a net loss, free cash flow turned negative, and it cut 2026 guidance while selling Diabetes Health for $235M.